ArticleDrug design, development and therapy2026
An Efficient Pharmacogenomic Assay for Psychotropic Drugs by Multiplex Fluorescence Melting Curve Analysis.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Long-term pharmacotherapy is the primary approach for alleviating the symptoms of mental disorders. Numerous pharmacogenomic studies have confirmed that genetic polymorphisms are key factors underlying inter-ethnic and inter-individual differences in drug response. Pharmacogenomic testing is an essential pathway to achieve precision medicine. Methods: In this study, seven common single nucleotide polymorphisms (SNPs) closely associated with the efficacy of antidepressants, and antipsychotics were screened and identified through comprehensive literature retrieval and mining of authoritative databases. These SNPs are located in the Results: The mFMCA system can accurately detect genomic DNA at concentrations as low as 100 copies/μL, and exhibits high specificity and no cross-reactivity. In the validation cohort (n=124), the mFMCA-derived genotypes achieved 100% concordance with Sanger sequencing. Furthermore, the high stability of the system was further evidenced by its consistent performance across varying DNA concentrations, different clinical samples, and multiple instruments. Conclusion: This study successfully established a dedicated and cost-effective mFMCA assay for psychotropic pharmacogenomic testing. The method provides an efficient, accurate, rapid, economical tool for personalized medicine in psychiatric care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.